Eppendorf Expands Bioreactor Offerings

DASGIP’s bioreactors offer volumes of 35 mL to 4 L, expanding Eppendorf’s offering to laboratory-scale bioreactors for a range of applications, including cell culture and process development. DASGIP also offers monitoring systems and software.

Hamburg and Jülich, Germany 1/5/12—Eppendorf has announced the acquisition of DASGIP, which develops and manufactures parallel bioreactor systems and software. Financial terms were not disclosed. “DASGIP’s high-quality parallel bioreactors and software solutions nicely complement the current offering of our New Brunswick product lines,” stated Eppendorf CEO Dirk Ehlers. “They allow us to forge a comprehensive suite of products for bioprocess research applications, development and scale-up, from 30 mL to 3,000 L.” The acquisition closed on January 2.

< | >